Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1290769 | 0.98 | TAAR1 (0.46) | TAAR1LTA4HPLA2G2ASOD1IDO1 | |
| SCHEMBL13411802 | 0.82 | TAAR1 (0.59) | TAAR1LTA4HPLA2G2AKDM4EESR1 | |
| SCHEMBL23067933 | 0.81 | TAAR1 (0.48) | TAAR1LTA4HPLA2G2AKDM4EESR1 | |
| SCHEMBL1239738 | 0.79 | TAAR1 (0.57) | TAAR1LTA4HPLA2G2A | |
| SCHEMBL13731094 | 0.78 | LOX (0.39) | TAAR1 | |
| Hydrochloric Acid SCHEMBL1623693 | 0.77 | TAAR1 (0.55) | TAAR1LTA4HPLA2G2AKDM4E | |
| SCHEMBL3922161 | 0.76 | ALDH1A1 (0.48) | SOD1 | |
| SCHEMBL5314766 | 0.76 | SOD1 (0.40) | SOD1IDO1 | |
| SCHEMBL4023626 | 0.76 | SOD1 (0.40) | SOD1IDO1 | |
| SCHEMBL6793710 | 0.76 | KAT6A (0.43) | LTA4HSOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | claimed |
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-118401521-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020210404-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2012045729-A1 | IMIDAZO [1, 2 -A] PYRIDINE AND PYRAZOLO [1, 5 -A] PYRIDINE DERIVATIVES AS TRPV1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-12 | — | — | WO | disclosed |
| WO-2000078737-A2 | ARYLOXY ETHYLAMINO TRIAZINES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | TAAR1 2684/4885LTA4H 2145/4885PLA2G2A 4534/4885 |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | TAAR1 2658/4885LTA4H 1761/4885PLA2G2A 3878/4885 |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | TAAR1 2870/4885LTA4H 1364/4885PLA2G2A 1166/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | TAAR1 2658/4885LTA4H 1761/4885PLA2G2A 3878/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | TAAR1 2658/4885LTA4H 1761/4885PLA2G2A 3878/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | TAAR1 2684/4885LTA4H 2145/4885PLA2G2A 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.